Cargando…

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations

BACKGROUND: Clozapine is the only medication licenced for treating patients with treatment-refractory schizophrenia. However, there are no evidence-based guidelines as to the optimal plasma level of clozapine to aim for, and their association with clinical and functional outcome. OBJECTIVE: We asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krivoy, Amir, Whiskey, Eromona, Webb-Wilson, Henrietta, Joyce, Dan, Tracy, Derek K., Gaughran, Fiona, MacCabe, James H., Shergill, Sukhwinder S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524694/ https://www.ncbi.nlm.nih.gov/pubmed/34676067 http://dx.doi.org/10.1177/20451253211037179

Ejemplares similares

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity
por: Lowe, Penelope, et al.
Publicado: (2017)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study
por: Casetta, Cecilia, et al.
Publicado: (2020)

Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation
por: Keshavarzi, Farinaz, et al.
Publicado: (2020)

Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis
por: Green, Alastair, et al.
Publicado: (2019)

Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report
por: Rodriguez, Victoria, et al.
Publicado: (2020)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

Rapid-onset clozapine-induced loss of glycaemic control: case report
por: Porras-Segovia, Alejandro, et al.
Publicado: (2017)

Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis
por: Beck, Katherine, et al.
Publicado: (2015)

Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis
por: Shirazi, Ayala, et al.
Publicado: (2016)

Resolution without discontinuation: heart failure during clozapine treatment
por: Whiskey, Eromona, et al.
Publicado: (2020)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

Possible pharmacogenetic factors in clozapine treatment failure: a case report
por: Whiskey, Eromona, et al.
Publicado: (2021)

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Sendt, Kyra-Verena, et al.
Publicado: (2018)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism
por: Kočovská, Eva, et al.
Publicado: (2017)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
por: Cho, J., et al.
Publicado: (2018)

A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)
por: Livermore, Cecilia, et al.
Publicado: (2022)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

S41. SHORT- AND LONG-TERM OUTCOMES OF VITAMIN D SUPPLEMENTATION IN CLOZAPINE TREATED CHRONIC SCHIZOPHRENIA PATIENTS
por: Krivoy, Amir, et al.
Publicado: (2018)

Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment
por: Gee, Siobhan, et al.
Publicado: (2015)

Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia
por: Tracy, Derek K., et al.
Publicado: (2015)

Correction to: Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia
por: Tracy, Derek K., et al.
Publicado: (2019)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
por: McQueen, Grant, et al.
Publicado: (2021)

Clozapine and COVID-19
por: Silva, Edward, et al.
Publicado: (2020)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

Treatment-resistant schizophrenia : the relationship between clozapine plasma concentration and clinical outcome
por: Kammoun, I., et al.
Publicado: (2022)

Biological Predictors of Clozapine Response: A Systematic Review
por: Samanaite, Ruta, et al.
Publicado: (2018)

Clozapine treatment and risk of severe COVID‐19 infection
por: Ohlis, Anna, et al.
Publicado: (2021)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t711lrnrbec9a3es4915pjkiek